Schrodinger sees FY25 software revenue growth 8%-13%

Software revenue growth is now expected to range from 8% to 13% compared to the prior expectation of 10% to 15%. Drug discovery revenue is now expected to range from $49 million to $52 million compared to the prior expectation of $45 million to $50 million. Software gross margin is now expected to range from 73% to 75% compared to the prior expectation of 74% to 75%. Operating expenses in 2025 are expected to be lower than 2024. Cash used for operating activities in 2025 is expected to be significantly lower than cash used for operating activities in 2024.